An Open-label Study in Healthy Male Subjects, to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK2269557, Administered as a Single Intravenous Microtracer (Concomitant With an Inhaled Non-radiolabelled Dose) and a Single Oral Dose

Trial Profile

An Open-label Study in Healthy Male Subjects, to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK2269557, Administered as a Single Intravenous Microtracer (Concomitant With an Inhaled Non-radiolabelled Dose) and a Single Oral Dose

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Nemiralisib (Primary) ; Nemiralisib (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease; Immunodeficiency disorders
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jan 2018 Status changed from recruiting to completed.
    • 27 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 13 Nov 2017 Planned End Date changed from 12 Dec 2017 to 22 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top